查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2004595

阿兹海默症诊断和治疗市场：2026年至2030年全球市场预测（按产品、药物类别、患者群体、疾病阶段、最终用户和分销管道划分）

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Drug Class, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast 2026-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年阿兹海默症诊断和治疗市场价值为 83.5 亿美元，预计到 2025 年将成长至 91.2 亿美元，复合年增长率为 9.50%，到 2030 年将达到 144.1 亿美元。

主要市场统计数据
基准年 2024 83.5亿美元
预计年份：2025年 91.2亿美元
预测年份 2030 144.1亿美元
复合年增长率 (%) 9.50%

这份文件揭示了影响阿兹海默症诊断和治疗未来发展的关键背景、科学挑战和行业驱动因素。

全球对抗阿兹海默症的斗争已迎来转折点。分子生物学、神经影像学和生物标记发现领域的进步正在重新定义疾病的诊断和治疗方式。曾经被视为不可避免的衰退，如今已成为严谨科学研究的对象，新的诊断方法和治疗策略正在不断出现。随着患者、看护者、临床医生和政策制定者对早期发现和更精准干预的迫切需求日益增长，学术界、产业界和监管机构的相关人员正积极行动起来，以满足这一迫切需要。

在快速发展的医疗保健生态系统中，找出能够重新定义阿兹海默症研究、诊断创新和治疗策略的变革性变化。

阿兹海默症领域正经历着翻天覆地的变革，这主要得益于生物标记检验、新一代影像技术以及数位医疗融合方面的突破性进展。最初，该领域仅依赖症状评估，但如今已转向整合分子诊断技术，以便在临床症状出现之前很久就检测到致病过程。这种转变正在加速标靶单株抗体、缓解疾病小分子药物以及旨在干预无症状或前驱期阶段的联合治疗的研发。

评估 2025 年美国关税对阿兹海默症。

美国将于2025年对诊断设备、药品生产原料和研究试剂加征新关税，这对阿兹海默症领域的各个层面都产生了影响。这些政策调整正在影响生物标记、造影剂和单株抗体组件的筹资策略。先前依赖低成本进口的机构现在正在评估国内产能，并重组供应链以降低关税带来的成本增加。

透过按产品、药物类别、患者人口统计特征、疾病阶段、最终用户和分销管道对阿兹海默症解决方案进行细分，解读获得的核心见解。

详细的市场区隔分析清楚展现了阿兹海默症治疗领域创新、投资和应用交会的领域。以产品类型检验市场发现，诊断方法（包括生物标记、基因检测、CT、MRI、EEG 和 PET 等影像技术以及简易精神状态检查 (MMSE) 等神经心理测试）与治疗支柱（包括联合治疗、药物治疗和非药物干预，例如认知刺激疗法）同步发展。血液生物标记和脑脊髓液 (CSF) 检测正逐渐成为增强早期检测能力的辅助诊断方法。

了解美洲、欧洲、中东、非洲和亚太地区阿兹海默症护理和研究的区域差异和战略机会。

要全面了解阿兹海默症的复杂现状，需要从区域观点。在美洲，完善的医疗基础设施、广泛的学术合作以及对生物标记研究的大量投入，正在加速先进诊断测试和治疗试验的推广应用。该地区率先部署了基于血液的生物标记检测组合，并利用广泛的远端医疗网络来扩大患者的就医管道，尤其是在资源匮乏的农村地区。

分析主要企业的策略部署、创新组合以及为重新定义阿兹海默症诊断和治疗市场而进行的合作努力。

阿兹海默症诊断和治疗领域呈现出生命科学创新者、生物技术先驱和成熟製药公司蓬勃发展的局面。主要企业已建立起整合生物标记发现、造影剂开发和新一代抗体工程的综合研发平台。它们的策略发展通常包括与学术机构签署合作研究协议、成立合资企业扩大生产规模以及透过许可协议拓展产品系列。

制定切实可行且具有前瞻性的建议，以支持产业领导者推动阿兹海默症的研究、诊断和治疗策略。

产业领导者必须采取多管齐下的策略，以充分利用不断发展的科学发现和不断变化的政策环境。首先，将血液衍生生物标记与神经影像学和基因检测结合，优先发展早期疗育平台，可以加快临床试验的患者招募速度，并提高诊断的可靠性。建立跨学科联盟，汇集分子生物学家、资料科学家和神经心理学家，将有助于开发下一代筛检方案和数位诊断工具。

详细介绍阿兹海默症市场研究中使用的严格调查方法，该方法结合了初步访谈、二手资料分析和专家检验。

本市场分析采用严谨的多阶段调查方法。首先，进行了全面的二级研究，涵盖同行评审文献、临床试验註册资讯、监管申报文件以及专有专利资料库，以揭示诊断技术和治疗方案的演变。提取了诊断准确率、治疗反应率和临床试验受试者入组指标等关键绩效指标（KPI），以建立比较基准。

本报告整合了关键发现、策略意义和未来前景，对阿兹海默症诊断和治疗方法的现状进行了全面评估。

本执行摘要阐述了阿兹海默症诊断和治疗领域中技术创新、政策转变和策略细分之间的动态互动。从先进生物标记检测和人工智慧成像技术的出现，到应对关税调整的策略倡议，该领域的特点是快速迭代和协作发展。透过产品类型、药物类别、患者族群、疾病阶段、最终用户和分销管道的详细细分，揭示了建立满足不同临床和市场需求的解决方案的复杂性和潜在机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：阿兹海默症诊断与治疗市场：按产品划分

  • 诊断
    • 生物标誌物
      • 血液衍生生物标记
      • 脑脊髓液（CSF）生物标记物
    • 基因检测
    • 诊断影像
      • 电脑断层扫描（CT）
      • 脑电图（EEG）
      • 磁振造影（MRI）
      • 正子断层扫描（PET）
    • 神经心理学测试
      • 用于确诊失智症的八份调查问卷
      • 简易精神状态测试
      • 蒙特娄认知评估
      • 神经精神病学症状评估调查问卷
  • 治疗方法
    • 联合治疗
    • 药物治疗
    • 非药物疗法
      • 行为干预
      • 认知刺激疗法

第九章：阿兹海默症诊断与治疗市场：按药物类别划分

  • 胆碱酯酶抑制剂
    • 多奈哌齐
    • Galantamine
    • Rivastigmine
  • 单株抗体
    • 阿杜卡奴单抗
    • 多纳内马
    • 利卡那单抗
  • NMDA受体拮抗剂

第十章：阿兹海默症诊断与治疗市场：按患者群体划分

  • 65-74岁
  • 75-84岁
  • 85岁或以上
  • 65岁以下

第十一章：阿兹海默症诊断与治疗市场：依疾病阶段划分

  • 阿兹海默症早期
  • 阿兹海默症晚期
  • 中期阿兹海默症

第十二章：阿兹海默症诊断与治疗市场：按最终用户划分

  • 学术和研究机构
  • 诊断中心
  • 居家照护设施
  • 医院和诊所

第十三章：阿兹海默症诊断与治疗市场：按分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十四章：阿兹海默症诊断与治疗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：阿兹海默症诊断与治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：阿兹海默症诊断与治疗市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国：阿兹海默症诊断与治疗药物市场

第十八章 中国：阿兹海默症诊断与治疗药物市场

第十九章 竞争情势

  • 2024年市场集中度分析
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2024 年
  • 2024年产品系列分析
  • 基准分析，2024 年
  • Abbvie Inc.
  • AC Immune SA
  • Alector, Inc.
  • Alzheon, Inc.
  • Amylyx Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc.
  • BioXcel Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cognoptix Inc.
  • Corium Inc.
  • Danaher Corporation
  • Denali Therapeutics Inc.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GE Healthcare
  • Grifols, SA
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd.
  • Merck & Co. Inc.
  • Muna Therapeutics
  • Novartis AG
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
  • TauRx Therapeutics Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 8.35 billion in 2024 and is projected to grow to USD 9.12 billion in 2025, with a CAGR of 9.50%, reaching USD 14.41 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 8.35 billion
Estimated Year [2025] USD 9.12 billion
Forecast Year [2030] USD 14.41 billion
CAGR (%) 9.50%

Unveiling the Critical Context, Scientific Imperatives, and Industry Drivers Shaping the Future of Alzheimer's Disease Diagnostics and Therapeutics

The global response to Alzheimer's disease has reached an inflection point. Advances in molecular biology, neuroimaging, and biomarker discovery are converging to redefine how the disease is diagnosed and treated. What was once considered an inevitable decline is now subject to rigorous scientific inquiry that is unlocking new diagnostic modalities and therapeutic approaches. With patients, caregivers, clinicians, and policymakers demanding earlier detection and more precise interventions, stakeholders across academia, industry, and regulatory bodies are mobilizing to meet this pressing need.

In recent years, diagnostic paradigms have shifted from purely clinical assessments to integrated models that leverage blood-based biomarkers, cerebrospinal fluid analyses, high-resolution magnetic resonance imaging, positron emission tomography, and sophisticated neuropsychological batteries such as the Montreal Cognitive Assessment and the Ascertain Dementia 8 instrument. At the same time, the therapeutic landscape is evolving beyond conventional drug monotherapies to embrace combination regimes, monoclonal antibodies targeting amyloid and tau, and non-pharmacological approaches like cognitive stimulation therapy and behavioral interventions.

This introduction sets the stage for an in-depth exploration of transformative shifts, tariff implications, segmentation insights, regional dynamics, and strategic recommendations. By synthesizing the latest data, expert perspectives, and methodological rigor, this report aims to equip decision-makers with the clarity and foresight needed to navigate the complex Alzheimer's ecosystem and to accelerate innovation for the millions of individuals and families affected worldwide.

Identifying the Transformative Shifts Redefining Alzheimer's Research, Diagnostic Innovation, and Therapeutic Strategies in a Rapidly Evolving Healthcare Ecosystem

The Alzheimer's disease arena is witnessing a profound transformation driven by breakthroughs in biomarker validation, next-generation imaging, and digital health integration. Early on, the field pivoted from relying solely on symptomatic assessments to embracing molecular diagnostics that detect pathogenic processes long before clinical onset. This shift has catalyzed the development of targeted monoclonal antibodies, disease-modifying small molecules, and combination strategies that aim to intervene at asymptomatic and prodromal stages.

Simultaneously, the integration of artificial intelligence and machine learning into imaging techniques such as MRI, CT, and PET scans is enabling unprecedented precision in lesion detection and progression monitoring. Genetic testing advancements are refining risk stratification frameworks, while neuropsychological testing innovations are enhancing cognitive profiling with tools like the Neuropsychiatric Inventory Questionnaire. On the therapeutic side, the blending of non-drug modalities-including cognitive stimulation and behavioral interventions-with pharmacological regimens is reshaping patient care models.

Healthcare systems are adapting to these innovations by expanding homecare settings, upgrading diagnostic center capabilities, and fostering cross-sector collaborations between hospitals, academic institutions, and technology partners. These dynamics are creating an ecosystem in which data interoperability, regulatory agility, and patient-centric design are increasingly recognized as critical enablers of successful Alzheimer's interventions. This section unpacks these transformative shifts, illustrating how interconnected advancements are redefining the research, development, and delivery of diagnostics and therapeutics in Alzheimer's disease.

Evaluating the Multifaceted Consequences of the 2025 United States Tariffs on Alzheimer's Disease Diagnostics, Therapeutics, and Global Supply Chain Dynamics

The introduction of new tariffs on diagnostic equipment, therapeutics manufacturing inputs, and research reagents by the United States in 2025 has rippled across the Alzheimer's disease landscape. These policy adjustments have influenced sourcing strategies for biomarkers, imaging agents, and monoclonal antibody components. Facilities that once relied on cost-effective imports are now evaluating domestic production capabilities and realigning supply chains to mitigate tariff-driven cost escalations.

On the diagnostics front, increased duties on specialized imaging hardware and cerebrospinal fluid assay kits have prompted diagnostic centers and academic research institutes to reassess capital expenditure and maintenance budgets. This in turn has accelerated the exploration of blood-based biomarker assays and decentralized testing models that reduce reliance on high-cost imports. Within therapeutics, the tariffs have impacted the raw materials essential for producing cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies such as aducanumab and lecanemab.

The cumulative effect has been a strategic pivot toward regional manufacturing hubs and localized distribution channels. Online and retail pharmacies are adapting to ensure patient access despite cost pressures, while hospital pharmacies are forging partnerships with domestic suppliers. Regulatory bodies are also streamlining approval pathways to encourage local production. As a result, stakeholders are balancing the need to maintain affordability and accessibility with the imperative to invest in innovation. This section delves into the nuanced implications of the 2025 tariffs and how they are driving adaptive strategies across the Alzheimer's diagnostics and therapeutics ecosystem.

Deciphering Core Insights from Product, Drug Class, Patient Demographics, Disease Stages, End Users, and Distribution Channel Segmentations Driving Alzheimer's Solutions

An in-depth segmentation analysis provides a granular view of where innovation, investment, and adoption converge in Alzheimer's disease care. Examining the market by product type reveals that diagnostic modalities-comprising biomarkers, genetic tests, imaging techniques such as CT, MRI, EEG, and PET, and neuropsychological batteries like the Mini-Mental State Exam-are advancing alongside therapeutic pillars that include combination therapies, drug treatments, and non-drug interventions such as cognitive stimulation therapy. Blood-based biomarkers and cerebrospinal fluid assays are emerging as complementary diagnostic streams that enhance early detection capabilities.

When viewed through the lens of drug class, cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine continue to serve as foundational therapies, while monoclonal antibodies including aducanumab, donanemab, and lecanemab are redefining disease-modifying treatment approaches. NMDA receptor antagonists also play a pivotal role in addressing symptomatic management. Patient demographic segmentation highlights the nuanced needs of those aged 65 to 74 years, 75 to 84 years, above 85 years, and the emerging considerations for individuals below 65 years who may present early-onset pathology.

Stage-based differentiation underscores the contrast between early-stage, middle-stage, and late-stage Alzheimer's, each demanding tailored intervention strategies and care delivery models. End users-spanning academic and research institutes, diagnostic centers, homecare settings, and hospitals and clinics-drive distinct adoption cycles, while distribution channels comprising hospital, online, and retail pharmacies shape accessibility and patient engagement. This comprehensive segmentation lens illuminates the multifaceted pathways through which diagnostics and therapeutics are researched, delivered, and integrated into patient care.

Uncovering Regional Variations and Strategic Opportunities across Americas, Europe Middle East and Africa, and Asia Pacific for Alzheimer's Care and Research

Regional perspectives are paramount to understanding the heterogeneous Alzheimer's disease landscape. In the Americas, robust healthcare infrastructure, extensive academic collaborations, and substantial investment in biomarker research have accelerated the adoption of advanced diagnostic assays and therapeutic trials. This region is pioneering blood-based biomarker panels and leveraging widespread telehealth networks to expand patient access, particularly in under-resourced rural communities.

Within Europe, Middle East, and Africa, regulatory convergence and cross-border research consortia are driving standardization of imaging protocols and genetic testing frameworks. Nations are investing in the integration of neuropsychological testing instruments, such as the Montreal Cognitive Assessment, into primary care pathways. Concurrently, localized production of monoclonal antibodies and small molecules is gaining traction, supported by favorable policy incentives and public-private partnerships.

In the Asia-Pacific region, rapid demographic aging, burgeoning homecare models, and digital health innovations are propelling demand for decentralized diagnostic tools and non-drug interventions. Behavioral interventions and cognitive stimulation programs are being adapted to local cultural contexts, while emerging biotech hubs are forging alliances with global pharmaceutical companies to accelerate clinical development. Each region's unique regulatory landscape, patient demographics, and healthcare delivery infrastructure create differentiated opportunities and challenges. This section explores these regional nuances, offering strategic guidance on how stakeholders can tailor their approaches to maximize impact and accessibility.

Analyzing Key Industry Players' Strategic Footprints, Innovation Portfolios, and Collaborative Efforts Redefining Alzheimer's Diagnostics and Therapeutics Markets

The Alzheimer's diagnostics and therapeutics sector is characterized by a dynamic mix of life science innovators, biotechnology pioneers, and established pharmaceutical firms. Leading companies have established comprehensive R&D platforms that integrate biomarker discovery, imaging agent development, and next-generation antibody engineering. Their strategic footprints often include collaborative research agreements with academic centers, joint ventures for manufacturing scale-up, and licensing arrangements to broaden their product portfolios.

In diagnostics, firms specializing in blood-based assays are forging partnerships with neuroimaging companies to develop multimodal screening solutions. Imaging technology providers are embedding artificial intelligence algorithms to enhance lesion detection and predictive analytics. On the therapeutics front, biotechnology companies focused on monoclonal antibodies are investing heavily in clinical pipeline expansion, while pharmaceutical incumbents are strengthening their small molecule and combination therapy offerings to maintain competitive positioning.

This landscape is further shaped by emerging players that are commercializing digital cognitive assessment platforms and novel non-drug interventions. Their agility in navigating regulatory surfaces and digital health approval pathways positions them as potential disruptors. Collectively, these enterprises are influencing pricing models, market access strategies, and global distribution frameworks. This section delves into the strategic initiatives, innovation trajectories, and collaborative networks of key companies, illuminating how they are driving the evolution of Alzheimer's disease diagnostics and therapeutics.

Formulating Practical and Forward-Looking Recommendations to Empower Industry Leaders in Advancing Alzheimer's Disease Research, Diagnostics, and Treatment Strategies

Industry leaders must adopt a multifaceted strategy to harness evolving scientific discoveries and shifting policy landscapes. First, prioritizing early-stage intervention platforms by integrating blood-based biomarkers with neuroimaging and genetic testing can accelerate clinical trial enrollment and improve diagnostic confidence. Establishing cross-disciplinary consortia that unify molecular biologists, data scientists, and neuropsychologists will catalyze the development of next-generation screening panels and digital diagnostic tools.

Second, diversifying therapeutic portfolios through strategic acquisitions or licensing deals can enhance access to novel monoclonal antibodies and non-drug interventions. By forging partnerships with academic research institutes and biotech startups, companies can leverage precompetitive data, share development risks, and expedite regulatory submissions. Simultaneously, investing in regional manufacturing capabilities and supply chain resilience will mitigate tariff impacts and ensure consistent product availability across diverse markets.

Third, adopting a patient-centric approach that tailors care pathways to demographic and disease-stage nuances will differentiate value propositions. This includes customizing treatment regimens for patients aged 65 to 74 years versus those above 85 years, and integrating cognitive stimulation therapy within homecare settings. Finally, embedding real-world evidence collection within diagnostic and therapeutic roll-outs will strengthen payer negotiations and support reimbursement frameworks. By executing these recommendations, industry stakeholders can align innovation with market imperatives, delivering sustainable growth and improved patient outcomes.

Detailing the Rigorous Research Methodology Integrating Primary Interviews, Secondary Data Analysis, and Expert Validation for Alzheimer's Market Study

This market analysis integrates a rigorous multi-stage research methodology. Initially, a comprehensive secondary review was conducted, encompassing peer-reviewed literature, clinical trial registries, regulatory filings, and proprietary patent databases to map the evolution of diagnostic technologies and therapeutic pipelines. Key performance indicators, such as diagnostic accuracy, treatment response rates, and clinical trial enrollment metrics, were extracted to establish comparative benchmarks.

Subsequently, primary research involved in-depth interviews with leading neurologists, research scientists, regulatory experts, and supply chain executives. These qualitative insights provided context on adoption barriers, reimbursement challenges, and strategic collaboration models. Concurrently, quantitative surveys were administered to diagnostic centers, hospitals, pharmacies, and homecare providers to capture deployment trends across different end-user segments and distribution channels.

Data triangulation ensured the validation of findings by cross-referencing primary inputs with secondary data points and incorporating feedback loops from industry advisory panels. This iterative validation process underpinned the development of segmentation frameworks, tariff impact assessments, and regional insights. Finally, an internal expert review panel, comprising neuropsychologists, pharmacologists, and health economists, scrutinized the analysis for methodological robustness and factual accuracy. This structured approach guarantees that the conclusions and recommendations presented are grounded in comprehensive evidence and reflective of the current Alzheimer's disease diagnostics and therapeutics ecosystem.

Synthesizing Critical Findings, Strategic Implications, and Future Outlook to Conclude the Alzheimer's Disease Diagnostics and Therapeutics Landscape Assessment

This executive summary has mapped the dynamic interplay of technological innovation, policy shifts, and strategic segmentation within Alzheimer's disease diagnostics and therapeutics. From the emergence of advanced biomarker assays and AI-enhanced imaging modalities to the strategic responses to tariff adjustments, the landscape is characterized by rapid iteration and collaborative advancement. Detailed segmentation across product types, drug classes, patient demographics, disease stages, end users, and distribution channels has revealed the complexity and opportunity inherent in tailoring solutions to diverse clinical and market needs.

Regional insights have underscored the importance of localized strategies, whether it be the Americas' emphasis on telehealth and rural access, the EMEA region's drive for regulatory harmonization, or the Asia-Pacific focus on decentralization and cultural adaptation of non-drug therapies. The strategic footprints of leading companies, combined with the actionable recommendations outlined, form a roadmap for stakeholders seeking to navigate competitive pressures, regulatory demands, and unmet clinical needs.

Looking ahead, the convergence of precision diagnostics, personalized therapeutics, and data-driven decision support systems is poised to accelerate disease modification efforts and improve patient outcomes. This conclusion synthesizes the critical findings and underscores the imperative for continued collaboration, innovation, and patient-centric focus as the Alzheimer's disease ecosystem evolves.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2024
  • 3.5. FPNV Positioning Matrix, 2024
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 8.1. Diagnostics
    • 8.1.1. Biomarkers
      • 8.1.1.1. Blood-Based Biomarkers
      • 8.1.1.2. Cerebrospinal Fluid (CSF) Biomarkers
    • 8.1.2. Genetic Testing
    • 8.1.3. Imaging Techniques
      • 8.1.3.1. Computed Tomography (CT) Scans
      • 8.1.3.2. Electroencephalogram (EEG)
      • 8.1.3.3. Magnetic Resonance Imaging (MRI)
      • 8.1.3.4. Positron Emission Tomography (PET)
    • 8.1.4. Neuropsychological Testing
      • 8.1.4.1. Ascertain Dementia 8
      • 8.1.4.2. Mini-Mental State Exam
      • 8.1.4.3. Montreal Cognitive Assessment
      • 8.1.4.4. Neuropsychiatric Inventory Questionnaire
  • 8.2. Therapeutics
    • 8.2.1. Combination Therapies
    • 8.2.2. Drug Therapies
    • 8.2.3. Non-Drug Therapies
      • 8.2.3.1. Behavioral Interventions
      • 8.2.3.2. Cognitive Stimulation Therapy

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by Drug Class

  • 9.1. Cholinesterase Inhibitors
    • 9.1.1. Donepezil
    • 9.1.2. Galantamine
    • 9.1.3. Rivastigmine
  • 9.2. Monoclonal Antibodies
    • 9.2.1. Aducanumab
    • 9.2.2. Donanemab
    • 9.2.3. Lecanemab
  • 9.3. NMDA Receptor Antagonists

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 10.1. 65-74 Years
  • 10.2. 75-84 Years
  • 10.3. Above 85 Years
  • 10.4. Below 65 Years

11. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 11.1. Early-Stage Alzheimer's
  • 11.2. Late-Stage Alzheimer's
  • 11.3. Middle-Stage Alzheimer's

12. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Centers
  • 12.3. Homecare Settings
  • 12.4. Hospitals & Clinics

13. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies

14. Alzheimer's Disease Diagnostics & Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Alzheimer's Disease Diagnostics & Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Alzheimer's Disease Diagnostics & Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Alzheimer's Disease Diagnostics & Therapeutics Market

18. China Alzheimer's Disease Diagnostics & Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2024
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2024
  • 19.3. Product Portfolio Analysis, 2024
  • 19.4. Benchmarking Analysis, 2024
  • 19.5. Abbvie Inc.
  • 19.6. AC Immune SA
  • 19.7. Alector, Inc.
  • 19.8. Alzheon, Inc.
  • 19.9. Amylyx Pharmaceuticals, Inc.
  • 19.10. AstraZeneca PLC
  • 19.11. Aurobindo Pharma Limited
  • 19.12. Biogen Inc.
  • 19.13. BioXcel Therapeutics Inc.
  • 19.14. Bristol-Myers Squibb Company
  • 19.15. Cognoptix Inc.
  • 19.16. Corium Inc.
  • 19.17. Danaher Corporation
  • 19.18. Denali Therapeutics Inc.
  • 19.19. Eisai Co., Ltd.
  • 19.20. Eli Lilly and Company
  • 19.21. F. Hoffmann-La Roche AG
  • 19.22. GE Healthcare
  • 19.23. Grifols, S.A.
  • 19.24. H. Lundbeck A/S
  • 19.25. Johnson & Johnson Services, Inc.
  • 19.26. Lupin Limited
  • 19.27. Luye Pharma Group Ltd.
  • 19.28. Merck & Co. Inc.
  • 19.29. Muna Therapeutics
  • 19.30. Novartis AG
  • 19.31. Quest Diagnostics Incorporated
  • 19.32. Sanofi S.A.
  • 19.33. Siemens Healthineers AG
  • 19.34. Takeda Pharmaceutical Company Limited
  • 19.35. TauRx Therapeutics Ltd.
  • 19.36. Teva Pharmaceutical Industries Ltd.
  • 19.37. Thermo Fisher Scientific Inc.
  • 19.38. Voyager Therapeutics, Inc.
  • 19.39. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 14. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 81. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 84. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 85. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 87. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 90. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 91. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 94. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 97. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 100. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 102. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 103. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 104. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 107. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 110. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 113. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 117. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 119. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 120. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 122. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 123. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 127. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 130. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 133. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 136. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 140. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 142. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 143. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 145. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 146. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 148. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 149. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 150. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 152. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 153. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 154. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 156. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 157. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 160. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 161. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 162. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 165. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 167. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 168. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 169. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 170. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 172. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 175. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 176. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 177. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NORTH AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 182. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 183. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 184. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 187. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 188. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 191. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 192. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. LATIN AMERICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 210. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 212. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 213. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 225. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 227. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 228. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 229. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 231. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 232. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 233. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 235. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 236. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
  • TABLE 237. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. MIDDLE EAST ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 239. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 240. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 241. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 242. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2030 (USD MILLION)
  • TABLE 243. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2030 (USD MILLION)
  • TABLE 244. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2030 (USD MILLION)
  • TABLE 245. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 246. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 247. AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. AFRICA AL